MEREO BIOPHARMA GROUP PLC (MREO) Net Margin
- 2025-06-30: Net Margin -2923.20%.
- 2023-12-31: Net Margin -910.90%.
- 2023-06-30: Net Margin -19.46%.
Complete source-backed net margin history.
- Available history
- 2023-06-30 to 2025-12-31
- Data captured
Historical Net Margin
| Date | Net Margin |
|---|---|
| 2025-06-30 | -2923.20% |
| 2023-12-31 | -910.90% |
| 2023-06-30 | -19.46% |
Annual Net Margin
| Date | Net Margin |
|---|---|
| 2025-12-31 | -8375.60% |
| 2023-12-31 | -294.66% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |